Two months ago the international Parkinson’s community came together under one roof in Barcelona, Spain for the 6th World Parkinson Congress. New friendships and collaborations were made, ideas were shared and hope for progress towards a cure for Parkinson’s disease remained at the forefront of WPC 2023.

A lot has happened around the world since the WPC 2023 took place, and we want to acknowledge the hardships some of our delegates and friends faced when returning home to dangerous fires, floods, and unstable political environments.

The WPC represents the global community - it’s our strong ties to the international community that makes our work so special and the Congress so unique. We are all impacted by these traumatic events and it’s important that wherever you are, you know the WPC family is
with you and you are not alone.

If your organization has been impacted by a natural disaster and the WPC community can help, please reach out to us by emailing our Executive Director who will do her best to make connections to help you through the events you are experiencing.

We would like to take this opportunity to share with you some video highlights from WPC 2023. These videos are for everyone, those of you who could not make it to Barcelona and even those of you who did attend the WPC 2023 in Barcelona - it would have been impossible to see all these talks with everything going on.

**Opening Ceremony**
Many people have been asking about videos from the Opening ceremony. You can now watch the Opening Ceremony in its entirety [here](#), or you can watch it in parts [here](#).

**Master Classes**
Videotaped during the WPC, you can now watch all of the WPC 2023 Master Class videos [here](#). These are short talks given by experts on the topics they presented on at WPC 2023.

We want to thank the experts listed below who took time out of their days while at the Congress to record these short talks.

**We also want to thank the sponsors who made this possible:**
Supernus, Amneal, ESTEVE
Hot Topics
The Hot Topics highlight emerging areas of study in Parkinson's research and disease management. Presenters covered topics such as genetics, the role of the diet in Parkinson's, the spread of alpha synuclein and more.

Twelve presenters were chosen from nearly 900 abstract submissions to share their Hot Topics presentations in the main plenary hall during the 6th World Parkinson Congress.

Watch all the Hot Topics here.

So what exactly is it that makes the WPC experience so meaningful for so many people? What's that secret sauce? WPC Steering Committee member and global Parkinson's Advocate, Sara Riggare, PhD, put pen to paper (or more likely fingers to keyboard) to explain this very question in her most recent blog.
So what is it about WPC that makes it so special?

The WPC is first and foremost an international scientific conference for Parkinson's research of the highest quality. Of course, there are also other conferences for which that is true. But, in addition, WPC is the only scientific conference in Parkinson's for ALL stakeholders. And this means that the WPC not only invites, but actively welcomes all parties interested in improving the situation for persons living with Parkinson's disease all over the world.

As a result of that, a young basic scientist doing research on a molecular level, after delivering a brilliant 10 minute presentation at WPC on their latest important findings can find themselves being asked a very insightful question on their chosen methods, not only by their usual peers from the scientific community but also by a person living with the condition that their research is ultimately intended to benefit.

That kind of interaction changes people. It changes both the person asking the question and the person answering because it makes them understand each other better. It also changes all of us listening to their interaction because it shows us that the way forward is together. It makes us all better humans and it makes healthcare and research better.

Finish reading Sara's blog

WPC Blog Highlight

NLX-112: a First-in-Class, Dual-Acting, Non-Dopaminergic, Drug Candidate for Treatment of Parkinson's Disease

by Adrian Newman-Tancredi, PhD, DSc

The main drug used to treat Parkinson's disease (PD) is levodopa, a substance which enhances brain levels of dopamine, a neurotransmitter that is compromised by the disease. Although levodopa is highly effective in managing the motor symptoms of PD, after extended treatment it can elicit troublesome involuntary movements called dyskinesia (levodopa-induced dyskinesia, LID). Current treatment options for LID are not satisfactory: lowering levodopa dosing can worsen parkinsonism, Deep Brain Stimulation requires invasive surgery and amantadine (the only approved drug for LID) is only partially effective and has side-effects of its own. Thus, well-tolerated and effective treatments for LID remain a
pressing medical need.

Read more

Watch WPC 2023 Hot Topics Presentation by Adrian Newman-Tancredi here.

The WPC Blog is made possible with support from Kyowa Kirin and Supernus.

A special announcement from WPC Organizational Partner, PMD Alliance. Click the image to find the resources they offer in Spanish and please share with others.

Saber es Vivir
Mes de la Herencia Hispana

4 Livestreams • 1 Month
Click here to receive event invites in your inbox

Sabes Spanish-Language Livestreams (confirmsubscription.com)
Our mailing address is:

1359 Broadway, Suite 1509, New York, NY 11018